Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation

NCT07687433 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer Patients

Interventions

DRUG: Long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib

Sponsor

Harbin Medical University